熱門資訊> 正文
2025-09-16 18:05
編者按:國際肺癌研究協會(IASLC)主辦的2025年世界肺癌大會(WCLC 2025)於2025年9月6日在西班牙巴塞羅那盛大召開,作為肺癌及其他胸部惡性腫瘤領域全球領先的多學科腫瘤學盛會,WCLC致力於傳遞領域最前沿進展,為世界各地的專家學者及研究者提供分享前沿研究成果、促進合作交流的平臺。近年來,中國創新葯在WCLC上頻頻嶄露頭角,成為大會備受矚目的焦點。會議期間,《腫瘤瞭望》在WCLC現場特邀IASLC前任首席執行官、美國紐約西奈山伊坎醫學院Fred Hirsch教授;IASLC前任主席、加州大學戴維斯分校綜合癌症中心David Gandara教授與復宏漢霖美國首席醫學官Ely Benaim博士,圍繞肺癌治療前沿與「中國方案」最新研究展開討論,本文整理討論精華內容,以饗讀者。
從WCLC重磅進展
看肺癌診療最新趨勢
Ely Benaim 博士
復宏漢霖美國首席醫學官
今年WCLC有哪些研究亮點?這些新研究成果將如何直接影響肺癌的臨牀實踐?
Dr.Ely Benaim: What are the research highlights of this year's World Conference on Lung Cancer(WCLC)? And how will these new findings directly impact clinical practice in lung cancer treatment?
Fred Hirsch 教授
IASLC前任首席執行官、美國紐約西奈山伊坎醫學院
剛剛結束的首場主席專場(Presidential Symposium)中有多項重要研究成果,首先是對比奧希替尼聯合化療與奧希替尼單藥治療的FLAURA2研究最新數據,先前聯合治療的無進展生存期(PFS)已顯示獲益,但其總生存期(OS)結果仍待明確。此次公佈的數據顯示,聯合治療的OS顯著優於單藥治療,但也伴隨毒性,臨牀中需充分評估治療風險。在EGFR靶向治療領域,隨着治療選擇日益豐富和新證據不斷涌現,治療策略排序仍是爭論焦點。事實上,基於早前FLAURA2研究的PFS結果,已有不少中心採用聯合治療,此次OS數據發佈將進一步支持其應用。
此外,對僅佔1-2%的ROS1陽性非小細胞肺癌(NSCLC),靶向新葯zidesamtinib公佈的數據也顯示,它對TKI經治患者仍有44%的較高客觀緩解率(ORR),對未接受TKI治療患者的顱內緩解率為83%;其它一些處於早期開發階段的新葯也值得關注。
Prof.Fred Hirsch: In the first Presidential Symposium that just concluded, a number of studies were highly important. The first key result is from the FLAURA2 study, which compared osimertinib plus chemotherapy with osimertinib monotherapy. While the progression-free survival (PFS) benefit of the combination therapy was already established, the conclusion of overall survival (OS) was still pending. The results released today showed that the combination therapy is indeed superior to monotherapy in terms of OS. Of course, the combination also leads to more toxicities, so the risks need to be fully assessed in practice.
I personally believe that how to arrange the most reasonable therapy sequence in EGFR-targeted therapy remains controversial, and with more and more options available, this field is very dynamic. Based on the previous PFS results, many centers were already using the combination therapy, and today's OS data from FLAURA2 study will further support its application.
Furthermore, in ROS1-positive patients, whose mutation frequency is only 1-2%, results from the new drug zidesamtinib were also released today. Its highlight is that it showed a high response rate (44%) even in patients who had previously received tyrosine kinase inhibitor (TKI) treatment, and the intracranial response rate in TKI-naive patients was 83%, which is quite impressive. Of course, there are many other promising new drugs in early-stage development.
David Gandara 教授
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
主席專場公佈的另一項研究顯示,ALK陽性NSCLC患者術后使用克唑替尼,相較僅觀察並未展現出更優的療效,結果初看令人失望;但同一治療場景中,阿來替尼帶來的獲益已被明確證實,因此這類研究的意義恰恰在於——通過「退一步」的陰性結果,幫我們更清晰地釐清藥物在疾病不同階段的價值。
除新的治療策略外,本屆WCLC還涵蓋多項重要議題,例如Hirsch教授尤為關注的生物標誌物研究,以及平臺型研究(master protocol)、實用型臨牀研究(pragmatic protocol)和富集設計(enrichment design)等新型臨牀研究設計方法。
而在小細胞肺癌(SCLC)領域,我在大會上首次報告了一項以血漿蛋白組學檢測將SCLC分為五個亞型的研究,其中僅兩個亞型對現有免疫+化療方案真正敏感,如何基於該分型精準治療,將是未來的重點探索方向。
Prof.David Gandara: As demonstrated in another study presented during the presidential symposium, postoperative treatment with crizotinib in ALK-positive NSCLC patients did not demonstrate superior efficacy compared to chemotherapy, with initial results appearing disappointing. However, clear benefits of alectinib in this therapeutic setting have already been established. This underscores the critical value of such studies—through "negative findings" from this "step back," we gain crucial insights to better clarify the value of targeted therapies at distinct disease stages.
In addition to new therapies, there is a lot of other important information at the WCLC conference, such as biomarkers that Professor Hirsch is most interested in, as well as new clinical trial designs like master protocols, pragmatic protocols, and enrichment designs, among others.
And in the field of small cell lung cancer(SCLC), I reported for the first time at this conference on a study that used a plasma proteomics approach to classify SCLC into five subtypes, of which only two truly respond to the existing immunotherapy plus chemotherapy regimen; how to carry out more precise treatment based on this subtyping will be a key area for future consideration.
聆聽肺癌治療「中國之聲」
合力推動國產創新葯惠及全球患者
Ely Benaim 博士
復宏漢霖美國首席醫學官
讓我印象尤為深刻的是,不論是在美國癌症研究協會(AACR)、美國臨牀腫瘤學會(ASCO)年會還是本次WCLC大會上,我們都看到了大量涌現的中國高質量研究數據報告,且涵蓋基礎與臨牀研究,例如復宏漢霖在本次WCLC上展示了有關PD-L1抗體偶聯藥物(ADC)、EGFR抗體及PD-1抗體(斯魯利單抗)等研究。兩位曾多次到訪中國,與眾多中國專家進行交流。請問兩位如何看待中國研究成果集中涌現?這將產生怎樣的影響?
Dr. Ely Benaim: What has particularly impressed me this year is the rapid increase of data from China, which we have seen presented at the annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), as well as at this WCLC conference. The data, including both basic and clinical research, and the quality of the clinical data is very high. For example, Henlius also presented projects at the conference regarding anti-PD-L1 antibody-drug conjugates (ADC), EGFR antibody, and PD-1 antibody(serplulimab). Both of you have been to China many times and have interacted with numerous Chinese experts. How do you view this explosion of data, and what kind of impact will it have on treatment?
David Gandara 教授
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
現在全球癌症治療最主要的新葯來源已是中國,中國不少機構技術進步很快,有最先進的設備和一流的科學家,更關鍵的是有龐大的患者羣體。像此前提到的ALK相關研究,在美國耗時八年完成,而在中國可能僅需兩年。新技術、優秀人才與龐大患者資源的結合,催生了大量創新葯和臨牀研究成果,很多甚至來自美國研究者不熟悉的企業。
在2025 ASCO年會上,我主持了名為「i-One」的分會場,當時我甚至把年會稱為「中國之年」,因為來自中國的新研究和報告極多,今天在WCLC,我們也看到了許多中國研究成果,這確實開啟了新的篇章。
Prof.David Gandara: Currently, the main source of new drugs for cancer treatment worldwide is already China. Many research centers in China are making very rapid technological progress, possessing the most advanced equipment and first-class scientists. More importantly, China has a huge patient population. For example, the previously mentioned study of ALK-positive patients took eight years to complete in the United States, while the same study, if conducted in China, might only take two years to complete. Combining new technologies, excellent talent, and a large patient population will lead to the emergence of a large number of innovative drugs and clinical research results, many of which are from companies that American researchers are not even familiar with yet.
At the recent 2025 ASCO annual meeting, I chaired a session called "i-One." At that time, I even referred to ASCO 2025 as the 「Year of China」 because there were simply too many new studies and reports from China. And today at WCLC, we also saw many research findings from China, which indeed is a new day, a new awakening.
Fred Hirsch 教授
IASLC前任首席執行官、美國紐約西奈山伊坎醫學院
當前中國在藥物研發和生物技術方面的發展確實令人矚目,但也帶來了一些挑戰,其中最大的挑戰在監管層面。例如我們希望看到中國研究在西方人羣中得到驗證,但這類研究往往耗時數年,所以后續應重點關注監管如何應對新葯新研究的涌現,且美國FDA和歐洲EMA都應積極參與。從患者角度來看,肺癌治療雖已進展顯著,但仍迫切需要新葯、新療法和新技術,儘早用上能精準匹配需求的治療,監管必須跟上這樣的快速發展。我們已計劃召開一系列匯聚各方代表的會議,坦誠探討監管在新形勢下的定位,以及如何適應並推動發展。
Prof.Fred Hirsch: The current development of China in drug research and biotechnology is indeed very impressive, but it also brings some challenges, the biggest of which is undoubtedly at the regulatory level. For example, we hope to see Chinese trials validated in Western populations, but such clinical trials often take many years to finish. Therefore, the next issue that needs to be focused on is how the regulatory system should respond to this surge of new drugs and new research, both the FDA and EMA should be involved. From the patient's perspective, even though significant progress has been made in the field of lung cancer, the patient's need for new drugs, new therapies, and new technologies is still very urgent, especially for treatments that can be accessed early and matched to the right patients. Therefore, the regulatory system must keep pace with this rapid development. We have already planned to convene some meetings, hoping to bring all parties together to openly discuss the position of regulation and how to adapt to and promote the current exciting pace of development.
David Gandara 教授
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
創新葯要獲得FDA批准,通常需提供西方人羣數據,過去,甚至可能要求中國企業重新開展臨牀研究。但是至少在我參與的ASTRIDE等研究中,情況已有所不同。FDA態度相當務實,認可在中國完成且療效出色的ASTRUM研究,僅要求提供斯魯利單抗在美國人羣中的療效和安全性與中國數據一致的證據,即允許通過「橋接研究」滿足監管要求,ASTRIDE研究正是這樣的研究。此外,斯魯利單抗也已獲歐洲EMA批准上市,這些都反映出監管思路的更新,能讓創新葯更快進入美國市場,讓患者更早獲益,對整個領域也是積極的改變。
同時,ASTRIDE研究旨在證明斯魯利單抗療效和毒性與現有藥物相當,那麼臨牀醫生為何要選斯魯利單抗,而不是更熟悉的同類藥物?毒性更低、療效更好,或為特定患者帶來更多獲益,纔是選擇它的理由,這正是ASTRIDE研究的價值:雖然它是一項橋接研究,但也融入了一些極具意義的分子層面分析,比如之前提到以血漿蛋白組學檢測,預測SCLC患者的獲益可能,即PROFIT SCLC檢測,如檢測結果為陽性,患者就適用斯魯利單抗,從而真正帶來新的治療機會。
Prof.David Gandara: For an innovative drug to gain FDA approval in the U.S., it has typically needed to provide data from Western populations, and previously, Chinese companies would even be asked to completely re-conduct their clinical studies. However, in at least some of the studies I have participated in, such as the ASTRIDE study, the situation has already been different. The FDA's attitude is quite pragmatic, recognizing the ASTRUM study, which was completed in China and showed excellent efficacy. It only required evidence that the efficacy and safety of serplulimab in the American population are consistent with the Chinese data, allowing us to use so-called 「bridging studies」 to meet regulatory requirements. We are currently conducting such a study. Furthermore, serplulimab has already been approved by the EMA in Europe. All of this reflects an updated regulatory mindset, allowing innovative drugs to enter the U.S. market more quickly, benefiting patients sooner. This is a positive change for the entire field.
In the mean time, the ASTRIDE study is designed to prove that serplulimab is comparable to existing drugs in both efficacy and toxicity, but what does this mean for its application in Europe or the U.S.? The key lies in the details of the study. Why would a clinician choose serplulimab over a more familiar drug of the same class? The reasons for selecting it would be lower toxicity, better efficacy, or greater benefit for specific patients. This is precisely where the value of the ASTRIDE study lies. Although it is a bridging study, it also incorporates some very meaningful molecular-level analyses, such as the plasma proteomics test mentioned earlier, which predicts the likelihood of benefit from immunotherapy for SCLC patients, we call it the PROFIT SCLC test. With this test, we can tell clinicians that if a patient's test result is positive, serplulimab is suitable for them, which truly provides a new treatment opportunity for these patients.
Ely Benaim 博士
復宏漢霖美國首席醫學官
我同意,這也是我與FDA打交道時的體會,例如對全球多中心試驗,FDA會要求美國患者佔比達10-30%,類似ASTRIDE研究證明創新葯在美國人羣中的療效和安全性,繼而進入審批討論流程,但我認為這一流程需繼續加快。儘管肺癌治療已取得巨大進步,晚期肺癌仍無法真正治癒,患者依然存在迫切治療需求,而我們的最終目標,至少是將肺癌轉變為一種可長期控制的慢性病,類似當前的大多數乳腺癌。
因此,我認為當前來自中國的臨牀研究熱潮,至少能在I/II期研究層面發揮重要作用。例如,一項入組40例患者的單臂研究或小規模隨機對照試驗,6個月就能完成並讀出結果,在過去幾乎不可想象,同時也能讓我們在進入審批流程前,更快速清晰地明確下一步方向。FDA重視並逐步認可中國數據,核心關切仍是這些研究是否適用於美國人羣。
Dr.Ely Benaim: This is also my experience with the FDA. For example, in global multi-center trials, the FDA will require the proportion of American patients to be 10-30%, enrolling American patients just like in the ASTRIDE study. This serves to prove that the efficacy and safety of the innovative drug in the American population are consistent with the Chinese data, and then the approval discussion process begins, but I believe the process still needs to be accelerated.
As mentioned before, while great progress has been made in lung cancer treatment, advanced lung cancer still cannot be truly cured, and patients continue to have an urgent need for treatment. Our ultimate goal is at least to turn lung cancer into a chronic disease that can be controlled long-term, just like most breast cancers now.
Therefore, I believe this wave of clinical research from China can at least play a significant role in promoting Phase I/II studies. For example, a single-arm study or a small-scale randomized controlled trial enrolling 40 patients could be completed and have its results read out in just 6 months, which was almost impossible in the past. This also allows us to know the next steps more quickly and clearly before entering the approval discussion process. Currently, the FDA is indeed looking seriously and accepting data from China, but it also wants to ensure that the study conclusions are applicable to the American population.
聚焦在研ADC新星
看后起之秀發力改寫診療格局
Ely Benaim 博士
復宏漢霖美國首席醫學官
Hirsch教授,作為PD-L1 ADC藥物HLX43美國臨牀研究的主要研究者(PI),您能否從ADC藥物在肺癌治療中的發展脈絡出發,闡釋HLX43的獨特機制與定位?縱觀ADC藥物從過去有限的角色到如今成為治療支柱的變遷,您認為HLX43未來將如何重塑NSCLC治療格局?
Dr. Ely Benaim: Professor Hirsch, you are the principal investigator (PI) for the U.S. portion of our other clinical study evaluating the anti-PD-L1 ADC drug, HLX43. Could you explain the unique mechanism of HLX43 and its positioning, starting from the developmental trajectory of ADC drugs in lung cancer treatment? Looking at the transformation of ADC drugs from their limited role in the past to becoming a pillar of treatment today, how do you think HLX43 will reshape the NSCLC treatment landscape in the future?
Fred Hirsch 教授
IASLC前任首席執行官、美國紐約西奈山伊坎醫學院
目前,ADC藥物的研發進展迅速,部分新型ADC在臨牀中展現出令人鼓舞的療效。然而,現有的PD-1/L1抗體療法仍存在明顯侷限——僅有約40%的患者能夠從中明確獲益,其余患者則出現初始無應答或繼發性耐藥,治療需求遠未滿足。因此,開發新型靶向PD-1/L1的藥物顯得尤為迫切。另一方面,肺鱗癌與非鱗癌在生物學行為上存在顯著差異,這種差異如何影響免疫治療的效果,仍需深入探索;同時也要求新一代PD-1/L1靶向藥物對鱗癌患者具備更強的療效。基於現有早期數據,靶向PD-L1的ADC藥物HLX43在上述兩個方向都表現出良好的潛力,值得進一步關注與研究。
總體而言,ADC發展極具前景也充滿挑戰。約一個月前我在《Clinical Cancer Research》上發表的評論文章就特別強調了這一點。ADC的靶點選擇多樣,有些ADC的靶點由基因突變驅動,有些則由蛋白過表達或拷貝數改變驅動。雖然靶向驅動基因本身可以有效抑制腫瘤生長,如靶向EGFR突變的TKI藥物,但ADC藥物的作用機制不同,這要回到其基本作用機制:ADC的起效依賴於抗體能否精準結合細胞表面蛋白,連接子及載荷毒素能否有效內化進入細胞,以及高效毒素的殺傷,以上三個關鍵環節仍有優化空間,而我認為HLX43在各個環節均有改進,有望進一步推動現有成果邁向更深層次的發展。
Prof. Fred Hirsch: The research and development of ADCs is currently progressing quickly, and the efficacy data of some new ADC drugs is very encouraging. We indeed need new drugs to assist existing PD-1/L1 antibodies, because only about 40% of patients can obtain clear clinical benefits from current treatments. Other patients either do not respond or develop resistance, and the treatment plans for these patients are still undecided, which is also an important area that needs new PD-1/L1-targeted drugs. In addition, the biological behavior of squamous cell carcinoma is significantly different from that of non-squamous cell carcinoma, We still need a deeper understanding of how this difference impacts immunotherapy, and new PD-1/L1-targeted drugs also need to be more effective for patients with squamous cell carcinoma. Based on the preliminary data, HLX43, a PD-L1-targeted ADC, has great potential in both above-mentioned areas, and we need to follow its development.
Overall, ADC is a very promising direction for development, but it is also full of challenges. A review article I published in Clinical Cancer Research about a month ago also specifically mentioned this point. We know that the selection of targets for ADCs is highly diverse. Some ADC targets are driven by genetic mutations, while others are driven by protein overexpression or copy number alterations. Although targeting the driver gene itself can effectively inhibit tumor growth—as seen with TKIs targeting EGFR mutations—the mechanism of action of ADC drugs is different, which brings us back to their fundamental mode of action: the mechanism of action of ADCs involves three key parts. First, whether the antibody can accurately bind to the cell surface protein; second, whether the linker and the drug can successfully enter the cell; and third, an effective payload of toxins. All three of these parts still have room for optimization. I personally believe that HLX43 has been optimized and improved in all three of the above-mentioned aspects, and therefore, I believe it has the potential to further advance the existing achievements to a deeper level.
David Gandara 教授
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
我還想補充一點,約兩年前ADC還被認為前景廣闊,但如今熱度有所回落,原因是當時出現了一批所謂「不限癌種(tumor-agnostic)」ADC,但其中許多都已失敗,如靶向CEACAM5、HER3及部分TROP家族靶點的ADC,其中的啟示就是——「靶點選擇至關重要」,也解釋了為何PD-L1是理想的ADC靶點,上百項研究都證實過它的重要性。我們必須迴歸ADC設計的原點,即靶向腫瘤特異性靶點,而我也非常期待HLX43后續研究結果。
Prof.David Gandara: I'd also like to add something: about two years ago, the prospects for ADC drugs were considered extremely broad, but now the enthusiasm has somewhat decreased. The reason is that a group of so-called "tumor-agnostic" ADCs appeared at that time. However, many of these drugs, such as ADCs targeting CEACAM5, HER3, and some TROP family targets, failed. This taught us that "the target is very important," which is also why PD-L1 is a suitable ADC target. Over 100 studies have now proven that PD-L1 is an extremely important target, so we must also return to the origin of ADC design, which is to target tumor-specific targets. I am also very much looking forward to the results of the subsequent related studies on HLX43.
Ely Benaim 博士
復宏漢霖美國首席醫學官
最令我印象深刻的是HLX43設計上的突破,如藥物-抗體比高(DAR)、效能強大、能被癌細胞快速內吞,且系統性毒性較低。這些創新靶點明確、遞送精準,未來很可能徹底改變我們對ADC的認知,帶來真正的治療新希望。
Dr.Ely Benaim: For me, what's most impressive is the breakthrough in its design. For example, HLX43 has a very high drug-to-antibody ratio (DAR), has high potency, and can be rapidly internalized by cancer cells, yet it has very low systemic toxicity. The design of these innovations have clear targets and precise drug delivery, and they are likely to change our perception of ADCs in the future, bringing genuine new hope for treatment.
從AI賦能到量身定製
展望未來肺癌精準治療
Ely Benaim 博士
復宏漢霖美國首席醫學官
如果五年后我們還在這里交流,屆時肺癌治療的新進展和新成果會是什麼?雖然目前熱議的是個體化治療、靶向治療等課題,但還有很多未被充分討論的方向,如人工智能(AI)在臨牀試驗設計和新葯研發中的應用。兩位認為未來肺癌治療領域的發展方向會是什麼?
Dr.Ely Benaim: If we were to meet here in five years, what new developments and achievements would we be discussing? While topics like personalized medicine and targeted therapy are currently being widely discussed, there are actually many other directions we haven't touched on, such as the application of artificial intelligence (AI) in clinical trial design and new drug R&D. What do you both believe the true direction of future development will be?
Fred Hirsch 教授
IASLC前任首席執行官、美國紐約西奈山伊坎醫學院
以SCLC為例,它的生物學行為與NSCLC存在顯著差異,且本身具有高度異質性,例如不同共突變可能影響治療效果。隨着對相關機制的理解不斷深入,我們也愈發認識到SCLC的複雜性。因此我們需更深入瞭解腫瘤的生物學本質,進一步研究生物標誌物,並探索基於標誌物制定治療方案。也許五年后,我們就將進入「聯合治療」的新時代,即基於科學依據和生物學行為,通過嚴謹設計將多種治療合理組合。
Prof.Fred Hirsch: Take SCLC for example, its biological behavior is significantly different from NSCLC, and it is highly heterogeneous itself, as different co-mutations can affect treatment. As our understanding of it deepens, the complexity of SCLC also increases. We still need a deeper understanding of the biological nature of tumors, to further study biomarkers, and to explore how to formulate treatment plans based on them. Perhaps in five years, we'll enter a new era of "combination therapy"—that is, a rational combination of multiple treatments, rigorously designed based on scientific evidence and biological behavior.
David Gandara 教授
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
我認為未來五年最重要的方向,是比當前更深入的個體化治療,過去我們曾用「精準腫瘤學」、「個體化治療」等名字,但對患者而言,最重要的是被醫生視為獨立的個體,而不是「百分之一」,只有這樣纔可能使不同患者獲得完全不同的治療。
下周我將在美國西南腫瘤協作組(SWOG)大會做主題報告,回顧過去二十年肺癌領域的變遷。二十年前,我們只有針對EGFR靶點的藥物,而到去年12月,指南要求檢測11個致癌基因,這意味着什麼?如果我們廣泛檢測,就像撒下一張大網,可以捕到很多「魚」;如果只做有限檢測,就如同小網捕魚,收效甚微。例如檢測EGFR突變時,就可能意外發現ROS1突變——上周我就有這樣一例患者,意外發現的基因突變徹底改變了治療。為每一位患者量身定製治療,纔是未來真正的方向。
Prof.David Gandara: I believe the most important direction for the next five years is personalized therapy, and it will be even more in-depth than it is today. We previously used names like "precision oncology" and "individualized therapy" to refer to it. But for the patient, the most important thing is that when they see a doctor, they hope the doctor will consider them as a unique individual, not just "one of a hundred," which is the only way for different patients to receive completely different treatment plans.
Next week, I will be speaking in the plenary session at the Southwest Oncology Group (SWOG) conference, reviewing the changes in the field of lung cancer over the past twenty years. First, I will look back at twenty years ago, when only targeted drugs for one target, EGFR, were available. By last December, according to the guidelines, we already needed to test for 11 oncogenes. What does this mean? If we test broadly, it's like casting a wide net and we can catch many "fish"; if we only do limited testing, it's like fishing with a small net, and the returns are minimal. For example, when testing for EGFR, we might incidentally discover a ROS1 mutation with a frequency of only 1%. I had one such patient last week; the accidental discovery of another gene mutation completely changed his treatment plan. Therefore, personalized therapy for each individual patient is the true direction of future development.
Ely Benaim 博士
復宏漢霖美國首席醫學官
談到聯合治療,我首先考慮的是安全性,因其往往受限於過高的毒性。在當前臨牀研發中,利用機器學習和AI,基於藥物結構預測毒性的做法越來越普遍。事實上,我們已經積累了海量數據——數百萬接受過不同藥物治療的患者,現有數據規模足以支持新工具在藥物進入人體試驗前,預測潛在可行的聯合方案。
因此我認為,機器學習必將對未來癌症治療產生重大影響。它不僅能輔助分析現有藥物的真實世界證據,還可基於已知的毒性和療效模式設計新葯,在臨牀試驗前預測出許多問題。復宏漢霖已在很多研發環節嘗試應用人工智能,許多企業也在做類似探索。二位認為機器學習和AI將如何推動新葯臨牀研發?
Dr.Ely Benaim: Your comments make me think that throughout our education and professional training, we have always placed a strong emphasis on biological characteristics, as well as on evidence and data. For example, when combination therapy is mentioned, the first thing I think of is safety, because the limitation of combination therapy is often its excessive toxicity. A practice that is becoming more common in the clinical R&D field is to use machine learning and artificial intelligence to predict toxicity based on drug structure. In fact, we have already accumulated a large amount of data—millions of patients have been receiving various different drug treatments. The amount of data is now large enough that new tools can predict which potential drug combinations are feasible before the drugs even enter human trials.
So in my opinion, machine learning will definitely have a big impact on cancer treatment in the future. It can not only help us analyze the real-world evidence of existing drugs, but also design new drugs based on existing toxicity and efficacy patterns, allowing many problems to be predicted before clinical trials. Our company is now trying to apply artificial intelligence in many stages of R&D, and many companies are doing similar things. So, how do you think machine learning and AI will help in the clinical R&D of new drugs?
Fred Hirsch 教授
IASLC前任首席執行官、美國紐約西奈山伊坎醫學院
在預測毒性及尋找毒性相關生物標誌物方面,我們長期以來一直面臨着數據不足,但如今有着海量數據和諸多數據收集機會,完全可能借助機器學習和AI來預測毒性。ADC藥物有毒性,聯合療法中使用的藥物也各有毒性,毒性問題是必須要應對的挑戰,需要相應制定合理的聯合治療方案、預測毒性,並最終實現毒性的預防。
Prof.Fred Hirsch: When it comes to predicting toxicity and finding toxicity-related biomarkers, we've actually always lacked sufficient data. But now we really have a massive amount of data and many opportunities for data collection, so it's entirely possible to use machine learning and AI to predict toxicity. Toxicity is a very significant problem—for example, the toxicity of the ADC drugs we discussed earlier, and of course, the drugs used in combination therapy each have their own toxicity, and that's a challenge we have to face. We need to learn how to formulate right drug combinations, predict toxicity, and even achieve toxicity prevention.
David Gandara 教授
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
目前關於AI仍有許多爭議,有人認為它會是救星,也有人擔心負面影響,關鍵在於如何運用。在腫瘤學領域,AI或機器學習可分析數千個潛在新靶點(包括蛋白或基因突變),進而篩選出其中十個最具研發前景的靶點——這正體現了AI的價值。
我舉一個實例:我在本次大會上關於SCLC分型的報告,完全基於機器學習完成。我們團隊分析了血液循環中的7000種蛋白質,研究了它們的生物學功能和與SCLC的關係,最終建立了一個分子分型體系。結合患者數據后,我們發現不同分型患者的生存期確實存在差異,並且僅有少數分型對免疫治療真正產生應答。我認為,這樣纔是未來:有方向、有指導地審慎使用AI而非隨意濫用,才能更快速、更有效地推動研究,讓治療早日惠及患者。
Prof.David Gandara: I think there's still a lot of controversy when it comes to AI. Some people think it'll be our savior, while others worry about its negative impacts. The key is how we use it. In oncology, an AI or machine learning program might analyze thousands of potential new targets, including proteins or gene mutations, and then screen out the ten most promising ones to advance. That's the value of AI.
I'll give you a practical example: my report on SCLC subtyping at this WCLC conference was conducted entirely using machine learning. Our team analyzed 7,000 proteins in blood circulation, studied their biological functions and the relationship between those functions and small cell lung cancer. We eventually established a molecular subtyping system, and then combined with patient data, we found that different subtypes do have differences in survival, and only a few subtypes truly respond to immunotherapy. In my opinion, this is the future: using AI in a directed and guided way, not arbitrarily. Only then can it help us advance research faster and better, allowing treatment to benefit patients sooner.
Fred Hirsch
IASLC前任首席執行官、美國紐約西奈山伊坎醫學院
西奈山Tisch癌症研究所(TCI)胸部腫瘤中心執行主任,TCI生物標誌物發現部副主任。Hirsch曾在科羅拉多大學擔任醫學和病理學教授18年,並曾擔任國際肺癌研究協會(IASLC)首席執行官。
David Gandara
IASLC前任主席、加州大學戴維斯分校綜合癌症中心
國際液體活檢協會首席醫療官
加州大學戴維斯分校綜合癌症中心主任高級顧問
夏威夷大學癌症中心轉化與臨牀研究項目兼職臨牀教授、名譽教授
國際肺癌研究協會(IASLC)前主席
Ely Benaim
復宏漢霖美國首席醫學官
全面負責復宏漢霖美國的臨牀醫學研發等相關事務,作為美國市場的醫學負責人,他同時支持復宏漢霖的研發和商務拓展等相關事宜。
Ely Benaim博士在委內瑞拉中央大學獲得醫學博士學位,曾在田納西大學兒科系擔任副教授,並曾在Amgen, Takeda Oncology, Berg, Rexahn Pharmaceuticals, Novocure, SonALAsense等公司擔任首席醫學官或其他重要職位。他在科學和醫學領域擁有超過25年的工作經驗,其中包括在生物製藥行業的17年工作經驗。